Correction: no evidence of an association between the T16189C mtDNA variant and late onset dementia (Gibson et al)

We believe that the title of Chinnery et al’s paper should be corrected because the data the authors present do not include an analysis of the 16189 variant of mtDNA (Table 1).

We defined the 16189 variant as the DNA sequence associated with a polyC tract, resulting from a T16189C transition that may generate heteroplasmic length variation, Table 1. Heteroplasmic length variation does not occur when the polymeric tract is interrupted by a c→t transition, which occurs at several different sites but commonly at nucleotide 16186 or 16192. Individuals with these additional polymorphisms are excluded from our definition of the 16189 variant because they no longer have a long homopolymeric c tract. The variant does not alter any codon sequences yet lies near to mtDNA control sequences, which can explain its effects on mitochondrial function. In studies of disease associations with variants in this region we choose to investigate the 16189 variant rather than any other sequence change, because of the likely functional effects of the homopolymeric C tract and heteroplasmic length variation.

Gibson et al have shown that the overall prevalence of the T16189C allele in their population is 12.6%, which is substantially higher than the 6.4–8.8% prevalence of the 16189 variant reported in other studies. This is because they have quantified the prevalence of the T16189C transition per se rather than the variant. Including these additional polymorphisms may dilute out a real association with the 16189 variant. The authors have shown that the T16189C transition per se is not a risk factor for late onset dementia, but to our knowledge this has not, in any case, been implicated with any disease phenotypes. However, they found that the heteroplasmic length variation, which implies the presence of the 16189 variant, was associated with a 2.2 fold increased risk. They did not however, quantify the relative risk for the 16189 variant per se, which could well be significant, in direct contradiction of their title. From their data, it is possible that the variant might in fact predispose to late onset dementia.

The 16189 variant is a risk factor for type 2 diabetes, thinness at birth, and aged 20 years iron loading in haemochromatosis, dilated cardiomyopathy, endometrial cancer, and other multifactorial disorders. This variant may provide mild functional defects in other muscles and tissues, resulting from a T16189C transition that may generate heteroplasmic length variation. This sequence associated with a polydC tract, interrupted by a c→t transition, which occurs at several different sites but commonly at nucleotide 16186 or 16192. Individuals with these additional polymorphisms are excluded from our definition of the 16189 variant because they no longer have a long homopolymeric c tract. The variant does not alter any codon sequences yet lies near to mtDNA control sequences, which can explain its effects on mitochondrial function. In studies of disease associations with variants in this region we choose to investigate the 16189 variant rather than any other sequence change, because of the likely functional effects of the homopolymeric C tract and heteroplasmic length variation.

Gibson et al have shown that the overall prevalence of the T16189C allele in their population is 12.6%, which is substantially higher than the 6.4–8.8% prevalence of the 16189 variant reported in other studies. This is because they have quantified the prevalence of the T16189C transition per se rather than the variant. Including these additional polymorphisms may dilute out a real association with the 16189 variant. The authors have shown that the T16189C transition per se is not a risk factor for late onset dementia, but to our knowledge this has not, in any case, been implicated with any disease phenotypes. However, they found that the heteroplasmic length variation, which implies the presence of the 16189 variant, was associated with a 2.2 fold increased risk. They did not however, quantify the relative risk for the 16189 variant per se, which could well be significant, in direct contradiction of their title. From their data, it is possible that the variant might in fact predispose to late onset dementia.

The 16189 variant is a risk factor for type 2 diabetes, thinness at birth, and aged 20 years iron loading in haemochromatosis.

Table 1 Sequences of identified variants

<table>
<thead>
<tr>
<th>Variant</th>
<th>Nucleotides</th>
</tr>
</thead>
<tbody>
<tr>
<td>16189 variant</td>
<td>cccctccc</td>
</tr>
<tr>
<td>Heteroplasmic length variants included within 16189 variant</td>
<td>cccctccc etccctccc</td>
</tr>
</tbody>
</table>

---


Poulton and Das comment on the results of our logistic regression analysis (Table 1 in our paper), and suggest that individuals with homoplasmic tract length heteroplasmy have a 2.2 fold increased risk of developing Alzheimer’s disease (AD) compared with controls. This would imply an association between their definition of the 16189 variant and late onset dementia. However, the confidence intervals for the relative risk of 2.2 are 0.85 to 5.81, comfortably including 1. The relative risk is therefore not statistically significant and does not support a link between AD and homoplasmic length tract heteroplasmy.

In our original study, we measured homoplasmic tract length heteroplasmy using a trimmed PCR approach with a fluorescent forward primer. However, not all individuals with a 161844-93 polyC tract also have length heteroplasmy. Therefore, to address the concerns of Poulton and Das experimentally, we directly sequenced the relevant region of the 16189 variant of mitochondrial DNA.
mDNA in all of the cases and controls that harboured the 16189C variant in our original study.7 using an established protocol.7 The frequency of the mtDNA 16189-3C polyC tract in our original control population corresponded to values reported in other studies (table 1); 39% of control individuals with the T16189C polymorphic variant had a 16189-3C polyC tract, corresponding to publicly available control sequence data (http://www.genpat.uu.se/mtDB/). We found no evidence of an association between AD or dementia with Lewy bodies and 16189-3C polyC tract in a cohort or neuropathologically defined cases and controls, either by logistic regression analysis, or by directly comparing cases and controls with Fisher’s exact test (table 1).

Acknowledgements

D M Turnbull and P F Chinnery receive support from the Wellcome Trust and the Alzheimer’s Research Trust.

S Meers, A M Gibson, D M Turnbull, P F Chinnery

Correspondence to: D P F Chinnery, Department of Neurology, The Medical School, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK; p.f.chinnery@ncl.ac.uk
doi: 10.1136/jmg.2004.022467
Received 5 May 2004
Accepted for publication 9 May 2004
Conflict of interest: none declared

References


Human Evolutionary Genetics: Origins, Peoples & Disease


With the near completion of the human genome sequence, and the exponential increase in associated information on inter-individual variability, there are enormous opportunities for using these data. Evolutionary geneticists are attempting to understand our origins and revisit the questions of the relative role of selection and drift. For medical geneticists, the search is now on for the genetic causes of complex disease, while forensic science is increasingly exploiting our interindividual differences to solve crimes. All these topics are inextricably linked. This superb textbook covers almost everything an undergraduate student in biology would need as a basis for any of these areas, but will in fact have a much wider readership. It starts as far back as the structure of DNA, chromosome structure, meiosis, mitosis, and so on, while covering in some depth anthropological, palaeontological, and archaeological evidence for the origins of modern humans, the extent and nature of genomic variation, and the principles of human population genetics. It explains clearly how the genome can be considered in blocks, owing to the pattern of historic and prehistoric recombinations and that these pieces of DNA, as well as the Y chromosome and mitochondrial DNA, track back to many ancestors who may have lived in different parts of the world.

This publication is timely, up to date, and has comprehensive coverage, without being too heavy to carry or costing too much. It is more than just a textbook, because it is possible to use it as bona fide reference material, with its logical content and problem issues. Thus as well as providing factual information, the book will stimulate the undergraduate to appraise observations and their interpretation critically. An important example is the pattern of error rates, and the potential impact of errors on interpretation of data. It answers questions that many of us get asked by our non-genetics friends, such as what exactly do we mean when we say that there is 1–2% sequence difference between humans and chimpanzees? How much do the different population groups of the world differ and is the term race meaningful? Clearly, as far as humans are concerned, it is not.

The book will also serve as a very useful introduction to molecular and population genetics for epidemiologists, anthropologists, and others who are new (or indeed not so new) to the field. It contains a wealth of information relevant for medical geneticists who are embarking on association studies. This, for example, includes the effects of selection and the effects of population admixture.

The book is very well laid out, with chapters grouped in six main sections, each of which aims to answer a question (Why study evolutionary genetics? How do we study genome diversity? How do we interpret genetic variation? Where and when did humans originate? How did humans colonise the world? How is an evolutionary perspective helpful?) There is a

Table 1. Frequency of the mtDNA 16189-3C polyC tract in control individuals, patients with dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD).

<table>
<thead>
<tr>
<th>Group</th>
<th>n (%)</th>
<th>mtDNA 16189-3C polyC tract</th>
<th>Comparison with controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>9</td>
<td>6.98 (3.24 to 12.83)</td>
<td>-</td>
</tr>
<tr>
<td>DLB (n = 97)</td>
<td>10</td>
<td>10.31 (5.06 to 18.14)</td>
<td>1.53 (0.60 to 3.93)</td>
</tr>
<tr>
<td>AD (n = 182)</td>
<td>11</td>
<td>6.04 (3.06 to 10.56)</td>
<td>0.83 (0.34 to 2.13)</td>
</tr>
</tbody>
</table>

*Exact 95% confidence intervals for the percentage were calculated using the method of Clopper and Pearson. Fisher’s two-tailed exact test. CI, confidence interval. Each group corresponds to the cohort of neuropathologically confirmed cases and controls reported in our paper.[1] Note that table 2 of our original report[1] only includes subjects where the complete APOE genotype was also known. This data was not available for two controls, one DLB case, and eight AD cases. The data from these cases are included in this table.

BOOK REVIEWS

Statistical Methods in Genetic Epidemiology


The contemporary research principles of genetic epidemiology are outlined in this book. The author clearly explains the research methodology and statistical analyses required to investigate important genetic epidemiological research questions. These include the following questions: Can one cluster in families? (familial aggregation); How does a disease cluster in families? (regression analysis); Can familial aggregation be explained by genetic or environmental factors? (gene–environment interaction); Can we localise the genetic defect? (linkage and association studies). The theory is mainly illustrated with examples on the genetic epidemiology of cancer. Genetic epidemiology is a world discipline, basic chapters on molecular genetics, epidemiology, statistics, and population genetics are included for those readers who need an introduction to any of these fields.

This book fascinates me because of its high didactic quality. The text is well organised and is easy to read. The content is interesting both to novices and to more advanced readers. The strength of this book is that it gives a complete overview of the different methods used in genetic epidemiology. Owing to its completeness, I would not be surprised if it were used in many semesters or courses on genetic epidemiology around the world. I would expect it also be very useful for the more advanced genetic epidemiologist as an up to date reference text. Readers interested in closely related disciplines such as population genetics, molecular genetics, behaviour genetics, statistical genetics, genomics, and bioinformatics will not find enough detail here and should look elsewhere.
good index and glossary, so that it is easy to look things up, and there are extensive references at the end of each chapter and recommendations for further reading. Indeed there are but few shortcomings. The figures and tables, which are on the one hand very useful and informative, do also have some weaknesses. Whether it is my failing eyesight or heterozygous manifestation of a colour vision anomaly, I often found the blue grey and black shadings and characters extremely difficult to distinguish. The figure legends could also sometimes have been more informative. However Mark Jobling and colleagues are to be congratulated—this book is a good buy, an excellent read, and is to be strongly recommended.

D M Swallow

CORRECTIONS
doi: 10.1136/jmg.2004.020644corr1

In the paper Recent advances in understanding haemochromatosis: a transition state (JMG 2004;41:721–30) figures 1 and 2 were incorrect. Below are the corrected figures.

A176CV has been changed to A176V and R224G has been changed to R224Q in figure 1.

N114D has been changed to N144D in figure 2. The journal apologises for these errors.
In the paper Recent advances (JMG 2004; 41:814–25) figure 2 was incorrect. Below is the corrected figures.

A small black bar has been inserted on the line representing the deletion present in the patient number 3273. The author apologizes for this error.

Figure 2
Correction: no evidence of an association between the T16189C mtDNA variant and late onset dementia (Gibson et al)

J Poulton and S Das

J Med Genet 2004 41: 957
doi: 10.1136/jmg.2004.019208

Updated information and services can be found at:
http://jmg.bmj.com/content/41/12/957.1

These include:

References
This article cites 11 articles, 3 of which you can access for free at:
http://jmg.bmj.com/content/41/12/957.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/